MP50-19 DOSE-FRACTIONATED ANTI-PSMA RADIOIMMUNOTHERAPY ( 177 LU-J591) FOR MCRPC
نویسندگان
چکیده
منابع مشابه
What's in a Label? Radioimmunotherapy for metastatic prostate cancer.
Prostate cancer has a highly tumor-restricted prostate-specific membrane antigen (PSMA) and may be the ideal solid-organ malignancy for treatment with radioimmunotherapy. Encouraging results using lutetium-177-labeled anti-PSMA monoclonal antibody J591 from a phase II study by Tawaga and colleagues support the continued clinical and preclinical development of radioimmunotherapy for solid tumors.
متن کاملRadiolabeling of monoclonal anti-vascular endothelial growth factor receptor 1 (VEGFR 1) with (177)Lu for potential use in radioimmunotherapy.
The main goal of this study was to optimize the radioimmunoconjugation of monoclonal anti-vascular endothelial growth factor receptor 1 (VEGFR 1) with (177)Lu as a potential angiogenic molecular tracer for radioimmunotherapy (RIT). For a successful radiolabeling, we chose cysteine derivative DTPA-NCS as the bifunctional chelating agent and optimized radiolabeling condition with modifications on...
متن کاملProstate-Specific Membrane Antigen-Based Therapeutics
Prostate cancer (PC) is the most common noncutaneous malignancy affecting men in the US, leading to significant morbidity and mortality. While significant therapeutic advances have been made, available systemic therapeutic options are lacking. Prostate-specific membrane antigen (PSMA) is a highly-restricted prostate cell-surface antigen that may be targeted. While initial anti-PSMA monoclonal a...
متن کاملPhase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer.
PURPOSE To assess the efficacy of a single infusion of radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 (lutetium-177; (177)Lu) by prostate-specific antigen (PSA) decline, measurable disease response, and survival. EXPERIMENTAL DESIGN In this dual-center phase II study, two cohorts with progressive metastatic castration-resistant prostate cancer received on...
متن کاملIndium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors
BACKGROUND J591 is a monoclonal antibody that targets the external domain of the prostate-specific membrane antigen (PSMA). Besides prostate cancer cells, it also targets the neovasculature of non-prostate solid tumors. We provide an analysis of the antibody mass-dose dependency of lesion uptake and normal tissue retention, together with an assessment of lesion detectability using (111)In-J591 ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Urology
سال: 2016
ISSN: 0022-5347,1527-3792
DOI: 10.1016/j.juro.2016.02.453